Furthermore, an open-label phase 0 clinical trial involving six patients with metastatic BC showed promising results, with c-MET-CAR-T cell therapy leading to tumor necrosis, hemorrhage, and significant infiltration of T-cells (CD3+, CD4+, and CD8+) and macrophages (CD68+) at the injection sites. The gene discussed is MET; the disease is neoplasm.